Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq in gWAT from diabetic mice treated with canagliflozin

ABSTRACT: RNA-seq in gWAT from diabetic mice treated with canagliflozin

PROVIDER: PRJNA1061139 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27428894_1.fastq.gz	Fastqsanger.gz
	SRR27428894_2.fastq.gz	Fastqsanger.gz
	SRR27428895_1.fastq.gz	Fastqsanger.gz
	SRR27428895_2.fastq.gz	Fastqsanger.gz
	SRR27428896_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

RNA-seq in gWAT from diabetic mice treated with canagliflozin

Project description:We found canagliflozin shows elimination of senescent cells from organs in age-related pathology mouse model including diabetes. To clarify detailed change by canagliflozin treatement, we conducted RNA-seq analysis in gonadal white adipose tissue(gWAT).

2024-04-06 | GSE252539 | GEO

Gene expression in the GWAT of ob/ob and ob/ob/Fsp27-/- mice

Project description:GWAT store most of the TAG in mice, ob/ob mice is an obese mice. Ob/ob/Fsp27-/- mice are lean when compared with ob/ob mice. The GWAT weight was dramatically reduced in ob/ob/Fsp27-/- mice. We next extract the total RNA from the GWAT of ob/ob and ob/ob/Fsp27-/- mice, to perform microaary analysis using Mouse Genome 430 2.0 arrays, Affymetrix. We then analysised the up-regulated and down regulated pathways. We extract the RNA of GWAT from 4 month old mice and hybridization on Affymetrix microarrays. We then analysis the data.

2015-04-17 | E-GEOD-59807 | biostudies-arrayexpress

Gene expression in the GWAT of ob/ob and ob/ob/Fsp27-/- mice

2015-04-17 | GSE59807 | GEO

Expression profile of BAT and gWAT from adipose tissue-specific Pgam1 deficient mice

Project description:To analyze the gene expression profile of BAT and gWAT from Pgam1 depletion mice, we performed whole genome microarray expression profiling using brown adipose tissue (BAT) and gonadal white adipose tissue (gWAT) from adipose tissue-specific Pgam1 knockout (KO) mice.

2022-04-11 | GSE186030 | GEO

Gene expression profile of gWAT SVF from adipose tissue-specific Pgam1 deficient mice

Project description:Epidydimal WAT from adipose tissue Pgam1 deficient mice shows the phenotype of beiging. We used single cell RNA sequencing (scRNA-seq) to characterize the beiging cells in gWAT.

2022-04-11 | GSE200374 | GEO

The effects of SGLT-2 inhibitors canagliflozin on hepatic transcription

Project description:We assessed the change in hepatic transciptional pattern after treatment with SGLT-2 inhibitors canagliflozin in a mice model of diet-induced obesity.

2021-05-13 | GSE114614 | GEO

Cardiac proteomics in diabetic cardiomyopathy mice treated with GLP-1 receptor agonist

Project description:the changes of cardiac proteomics in diabetic cardiomyopathy mice treated with GLP-1 receptor agonist

2021-09-10 | PXD028452 |

Proximal tubular epithelial specific transcriptomics of diabetic mice treated with dapagliflozin

Project description:We show the proximal tubular specific pathway analysis demonstrating the downregulation of oxidative phosphorylation in dapagliflozin treated db/db mice, a type 2 diabetic model. After 8-week treatment of dapagliflozin for db/db mice having proximal tubule specific tdTomato reporter, tdTomato-positive cells were isolated by FACS. Pathway analysis of RNA sequence of isolated tubular epithelia revealed that oxidative phosphorylation was downregulated in dapagliflozin-treated mice. However, depletion of renal tissue ATP content in db/db mice was ameliorated by dapagliflozin administration. Pimonidazole staining demonstrated that renal cortical tissue hypoxia was noted in db/db mice, which was improved by dapagliflozin administration. These findings suggest that dapagliflozin can ameliorated the excessive oxygen and ATP consumption and subsequent tissue hypoxia in diabetic kidney, which may explain, in part, the responsible mechanisms of renoprotecitive effect by dapagliflozin.

2022-09-28 | GSE185801 | GEO

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy

Project description:Radiotherapy (RT) is a non-invasive standard treatment for prostate cancer (PC). However, PC develops radio-resistance, highlighting a need for agents to improve RT response. Canagliflozin, an inhibitor of sodium-glucose co-transporter-2, is approved for use in diabetes and heart failure, but is also shown to inhibit PC growth. However, whether canagliflozin can improve RT response in PC remains unknown. Here, we show that well-tolerated doses of canagliflozin suppress proliferation and survival of androgen-sensitive and insensitive human PC cells and tumors and sensitize them to RT. Canagliflozin blocks mitochondrial respiration, promotes AMPK activity, inhibits the MAPK and mTOR-p70S6k/4EBP1 pathways, activates cell cycle checkpoints, and inhibits proliferation in part through HIF-1 suppression. Canagliflozin mediates transcriptional reprogramming of several metabolic and survival pathways known to be regulated by ETS and E2F family transcription factors. Genes downregulated by canagliflozin are associated with poor PC prognosis. This study lays the groundwork for clinical investigation of canagliflozin in PC prevention and treatment in combination with RT.

2023-09-10 | GSE239688 | GEO

Proximal tubular epithelial specific transcriptomics of diabetic mice treated with dapagliflozin

Project description:Proximal tubular epithelial specific transcriptomics of diabetic mice treated with dapagliflozin

| PRJNA770888 | ENA